685 related articles for article (PubMed ID: 20530286)
21. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
22. Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes.
Macri C; Dumont C; Panozza S; Lahoud MH; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
Mol Immunol; 2017 Jan; 81():143-150. PubMed ID: 27978488
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
Cioca DP; Deak E; Cioca F; Paunescu V
J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
[TBL] [Abstract][Full Text] [Related]
24. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
[TBL] [Abstract][Full Text] [Related]
25. Signaling and immune regulatory role of the dendritic cell immunoreceptor (DCIR) family lectins: DCIR, DCAR, dectin-2 and BDCA-2.
Kanazawa N; Tashiro K; Miyachi Y
Immunobiology; 2004; 209(1-2):179-90. PubMed ID: 15481152
[TBL] [Abstract][Full Text] [Related]
26. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes.
Kamphorst AO; Guermonprez P; Dudziak D; Nussenzweig MC
J Immunol; 2010 Sep; 185(6):3426-35. PubMed ID: 20729332
[TBL] [Abstract][Full Text] [Related]
27. Langerhans Cell-Dendritic Cell Cross-Talk via Langerin and Hyaluronic Acid Mediates Antigen Transfer and Cross-Presentation of HIV-1.
van den Berg LM; Cardinaud S; van der Aar AM; Sprokholt JK; de Jong MA; Zijlstra-Willems EM; Moris A; Geijtenbeek TB
J Immunol; 2015 Aug; 195(4):1763-73. PubMed ID: 26170391
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
29. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
[TBL] [Abstract][Full Text] [Related]
30. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
31. HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells.
Florentin J; Aouar B; Dental C; Thumann C; Firaguay G; Gondois-Rey F; Soumelis V; Baumert TF; Nunès JA; Olive D; Hirsch I; Stranska R
Blood; 2012 Nov; 120(23):4544-51. PubMed ID: 23053572
[TBL] [Abstract][Full Text] [Related]
32. Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines.
Klauber TCB; Laursen JM; Zucker D; Brix S; Jensen SS; Andresen TL
Acta Biomater; 2017 Apr; 53():367-377. PubMed ID: 28153581
[TBL] [Abstract][Full Text] [Related]
33. IL-10 promotes homeostatic proliferation of human CD8(+) memory T cells and, when produced by CD1c(+) DCs, shapes naive CD8(+) T-cell priming.
Nizzoli G; Larghi P; Paroni M; Crosti MC; Moro M; Neddermann P; Caprioli F; Pagani M; De Francesco R; Abrignani S; Geginat J
Eur J Immunol; 2016 Jul; 46(7):1622-32. PubMed ID: 27129615
[TBL] [Abstract][Full Text] [Related]
34. Cross-presentation of dead-cell-associated antigens by DNGR-1
Balam S; Kesselring R; Eggenhofer E; Blaimer S; Evert K; Evert M; Schlitt HJ; Geissler EK; van Blijswijk J; Lee S; Reis e Sousa C; Brunner SM; Fichtner-Feigl S
Eur J Immunol; 2020 Dec; 50(12):2041-2054. PubMed ID: 32640051
[TBL] [Abstract][Full Text] [Related]
35. Toll-like receptor 7 controls the anti-retroviral germinal center response.
Browne EP
PLoS Pathog; 2011 Oct; 7(10):e1002293. PubMed ID: 21998589
[TBL] [Abstract][Full Text] [Related]
36. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.
Ramakrishna V; Treml JF; Vitale L; Connolly JE; O'Neill T; Smith PA; Jones CL; He LZ; Goldstein J; Wallace PK; Keler T; Endres MJ
J Immunol; 2004 Mar; 172(5):2845-52. PubMed ID: 14978085
[TBL] [Abstract][Full Text] [Related]
37. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
[TBL] [Abstract][Full Text] [Related]
38. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities.
Mohty M; Vialle-Castellano A; Nunes JA; Isnardon D; Olive D; Gaugler B
J Immunol; 2003 Oct; 171(7):3385-93. PubMed ID: 14500632
[TBL] [Abstract][Full Text] [Related]
39. Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I.
Horrevorts SK; Duinkerken S; Bloem K; Secades P; Kalay H; Musters RJ; van Vliet SJ; García-Vallejo JJ; van Kooyk Y
Front Immunol; 2018; 9():1231. PubMed ID: 29963041
[TBL] [Abstract][Full Text] [Related]
40. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity.
Oh JZ; Kedl RM
J Immunol; 2010 Oct; 185(8):4602-8. PubMed ID: 20844205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
